Edgewise Therapeutics (EWTX) Current Assets (2020 - 2026)

Edgewise Therapeutics has reported Current Assets for 7 years, with the latest figure at $509.8 million in Q1 2026.

• Quarterly Current Assets rose 15.03% year-over-year to $509.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $509.8 million (up 15.03% YoY) and the FY2025 annual result came in at $543.4 million, up 14.28% from the prior year.
• Current Assets retreated to $509.8 million in Q1 2026 per EWTX's latest filing, from $543.4 million in the prior quarter.
• Over five years, Current Assets peaked at $603.3 million in Q2 2025 and troughed at $253.3 million in Q2 2022.
• A 5-year average of $425.5 million and a median of $443.2 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2024: Current Assets declined 19.51% in 2023, then soared 67.64% in 2024.
• Over 5 years, Current Assets stood at $357.0 million in 2022, then slipped by 8.4% to $327.0 million in 2023, then surged by 45.41% to $475.5 million in 2024, then rose by 14.28% to $543.4 million in 2025, then dropped by 6.18% to $509.8 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $509.8 million, $543.4 million, and $573.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.